Ozempic generated A$21 billion of sales in 2023 alone. So how was it developed? And how are its new competitors, Mounjaro and Zepbound, different?
Patients need to know that treatments are recommended based on patient need, not pharma company interests. That’s why it’s important to know how much Big Pharma is paying to health-care providers and organizations.
(Shutterstock)
Canada has a lack of transparency about Big Pharma’s payments to health-care providers and organizations. Disclosure is voluntary, and there’s no central data on even the few companies that do report.
A new study has found no evidence that people’s beliefs in conspiracy theories increase over time. They can even change their minds – just not that often.
So many diseases to treat, so little money and time.
Andriy Onufriyenko/Moment via Getty Images
Drug development takes a great deal of time, money and effort. While future profits play a big factor in which diseases gets prioritized, advocacy and research incentives can also tilt the scale.
Under a pharmacare plan, a single bargaining agent negotiates for lower prices from drug companies.
(Shutterstock)
Pharmaceutical and insurance industries that could lose profit through lower drug prices are not happy that a pharmacare bill is planned for fall. They are speaking out and mobilizing their allies.
Canadians pay high drug prices, but the pharmaceutical industry claims it is a ‘key partner in economic resilience, recovery and growth.’
(Shutterstock)
Canadians pay very high drug costs, but Canada also does not receive the same economic benefits from pharmaceutical industry investments as other countries do.
Health Canada’s new drug licensing proposal contains no mechanism for making fast-tracked medicines affordable.
THE CANADIAN PRESS/Ryan Remiorz
The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
People for millennia have used what grows around them as medicine.
LorenzoT81/iStock via Getty Images Plus
An anthropology course explores how peoples and cultures around the world use nature-based medicines to heal.
When regulatory agencies like Health Canada approve a new drug, they require the drug company to continue monitoring the product’s safety.
(Shutterstock)
Health Canada continues to monitor newly approved drugs to determine if the benefits identified in the pre-market trials hold up to further scrutiny. Canadians need better access to that information.
Research confirms the adverse effects of social media on mental health.
Shutterstock
Some commercial products and practices are directly linked to avoidable ill health, planetary damage, and social and health inequity. Large transnational corporations are especially to blame.
The pharma industry warned that if proposed new prescription price guidelines go ahead, drug launches would be delayed and ‘Canadian patients will be deprived of potentially life-saving new medicines.’
(Shutterstock)
The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
Drug patents don’t necessarily spur companies to innovate so much as restrict access to their IP.
Andrii Zastrozhnov/iStock via Getty Images Plus
The Medicines Patent Pool was created to promote public health, facilitating generic licensing for patented drugs that treat diseases predominantly affecting low- and middle-income countries.
COVID-19 patients receive oxygen as they lie in their beds in the intensive care unit of a hospital in Machakos, Kenya, in August 2021.
(AP Photo/Brian Inganga)
A major lesson from the COVID-19 pandemic is the need to decolonize transnational governance so that the world is better able to handle both future and current global crises.
OxyContin, an opioid drug heavily marketed by Purdue Pharma, is associated with billions of dollars of health-care costs in Canada related to the opioid crisis.
(AP Photo/Toby Talbot)
The Purdue Pharma settlement is paltry compared to costs of the opioid crisis. Without major changes to pharma industry regulation, there is little reason to think a similar crisis won’t occur again.
Global Justice campaigners in London stand by fake coffins to highlight global COVID-19 deaths. If pharma companies waived intellectual property rights, it would be easier for low- and middle-income countries to access COVID-19 vaccines.
(AP Photo/Alastair Grant)
Ronald Labonte, L’Université d’Ottawa/University of Ottawa
Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
Drug repurposing can redeem failed treatments and squeeze out new uses from others. But many pharmaceutical companies are hesitant to retool existing drugs without a high return on investment.
Changes to the Patented Medicine Prices Review Board regulations, which are intended to help lower drug costs in Canada, were originally scheduled to take effect in July 2020.
(Shutterstock)
Changes to Canada’s Patented Medicine Prices Review Board regulations have been postponed for a fourth time in two years as Canadians continue to pay some of the highest drug prices in the world.
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney